Simplify everything from site selection to study close-out
Velocity unifies operational processes to provide world-class sites, reliable enrollment, and predictably high performance for your trials.
News
Why Site Selection Needs a Data Reset and How AI Can Deliver It
By Andrew Reina, Chief Revenue Officer Clinical research is at an inflection point. Sponsors and CROs are being asked to deliver trials that start faster, enrol more predictably, and generate … Read more
An Interview with Matthew Wenker, MD on the People-First Principles that Shape Good Clinical Research
Over the course of his career, Matthew Wenker, MD, has moved from hospital wards to Phase I units and, eventually, to leading research across three Velocity sites in Cincinnati. Along … Read more
Lilly’s Once-Weekly Insulin Efsitora Demonstrated A1C Reduction and Safety Profile Consistent With Daily Insulin in Phase 3 Trials
Across multiple Phase 3 trials, Eli Lilly and Company’s once-weekly insulin efsitora alfa matched daily basal insulin in A1C reduction and demonstrated a similar safety profile. “The novel fixed-dose regimen … Read more
Positive Topline Results Announced for ACCESS Studies for Aleniglipron (Oral GLP-1 RA)
Congratulations to the Structure Therapeutics team for announcing positive topline data from its ACCESS clinical program for aleniglipron, an oral GLP-1 receptor agonist. Julio Rosenstock, MD, Chair of the ACCESS … Read more